"Oncolytic Virotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.
| Descriptor ID |
D050130
|
| MeSH Number(s) |
E02.095.601
|
| Concept/Terms |
Oncolytic Virotherapy- Oncolytic Virotherapy
- Oncolytic Virotherapies
- Virotherapies, Oncolytic
- Virotherapy, Oncolytic
- Oncolytic Virus Therapy
- Oncolytic Virus Therapies
- Therapies, Oncolytic Virus
- Therapy, Oncolytic Virus
- Virus Therapies, Oncolytic
- Virus Therapy, Oncolytic
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Virotherapy".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Virotherapy".
This graph shows the total number of publications written about "Oncolytic Virotherapy" by people in this website by year, and whether "Oncolytic Virotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 6 | 0 | 6 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 1 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
| 2024 | 1 | 0 | 1 |
| 2025 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Virotherapy" by people in Profiles.
-
Translational advancement of immunotherapeutics against pediatric central nervous system tumors. Adv Cancer Res. 2025; 167:327-358.
-
The promise of immunotherapy for central nervous system tumours. Nat Rev Immunol. 2026 Mar; 26(3):213-229.
-
Systematic Targeting of GD2-Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform. Adv Sci (Weinh). 2025 Oct; 12(38):e15356.
-
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025 07; 643(8070):219-229.
-
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity. Nat Commun. 2025 Apr 24; 16(1):3874.
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).
-
Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
-
Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models. J Transl Med. 2023 07 06; 21(1):444.
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
-
An Ion-Enhanced Oncolytic Virus-Like Nanoparticle for Tumor Immunotherapy. Angew Chem Int Ed Engl. 2022 11 07; 61(45):e202210487.